<DOC>
	<DOCNO>NCT00545974</DOCNO>
	<brief_summary>The primary objective study determine whether memantine effective slow rate behavioral decline frontotemporal dementia . The secondary objective study assess safety tolerability long-term treatment memantine patient frontotemporal dementia ( FTD ) semantic dementia ( SD ) . To determine whether memantine effective slow rate cognitive decline frontotemporal dementia . To evaluate whether memantine delay decrease emergence parkinsonism frontotemporal dementia . The tertiary objective study determine whether treatment memantine affect change weight</brief_summary>
	<brief_title>Memantine ( 10mg BID ) Frontal Temporal Subtypes Frontotemporal Dementia</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled trial memantine 10 mg twice daily versus placebo , ratio 1:1 , receive active drug placebo . Screening enrollment plan last approximately one year . A Data Safety Monitoring Board , consist clinical pharmacist 3 neurologist review AE report approximately every 3 month study initiation . The DSMB notify principal investigator , study sponsor CHR significant concern raise review AE data . An interim analysis efficacy data conduct 50 % target enrollment population complete 26 week drug treatment . Including screen off-drug follow , subject participate study approximately 34 week . The entire study anticipate last 86 week enrollment complete within one year study initiation . The targeted enrollment 140 .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>A subject must meet ALL follow criterion consider enrollment study : 1 . Signed date write informed consent obtain subject subject 's caregiver accordance local IRB regulation . 2 . Must meet criterion Neary et al . criterion frontotemporal dementia ( FTD ) semantic dementia ( SD ) 3 . Age : 4080 4 . CT MRI brain within 12 month consistent diagnosis FTD SD . 5 . MMSE ≥ 15 screen visit . 6 . Judged investigator able comply neuropsychological evaluation baseline . 7 . Must reliable caregiver accompany subject study visit . Caregiver must read , understand speak English fluently order ensure comprehension inform consent form informantbased assessment subject . Caregiver must also frequent contact subject ( least 3 time per week one hour ) willing monitor study medication compliance subject 's health concomitant medication throughout study . 8 . In opinion investigator , patient caregiver compliant protocol high probability complete study . Any one follow exclude subject enrol study : 1 . Insufficient fluency English complete neuropsychological functional assessment . 2 . Concurrent Motor Neuron Disease judge investigator bulbar upper extremity impairment baseline would interfere neuropsychological assessment , expect lead impairment within one month . 3 . Exclusion criterion list Neary criterion . Diagnosis progressive nonfluent aphasia Neary criterion . 4 . Use memantine within 4 week prior randomization . 5 . Evidence neurological psychiatric disorder preclude diagnosis FTD ( include , limited , stroke , Parkinson 's disease , psychotic disorder , severe bipolar unipolar depression , seizure disorder , head injury loss consciousness ) within past year . 6 . Concurrent treatment acetylcholinesterase inhibitor , antipsychotic agent , mood stabilizer ( valproate lithium ) benzodiazepine ( temazepam zolpidem ) , use agent within 4 week prior randomization . Atypical antipsychotic agent may start baseline visit felt medically necessary investigator record secondary outcome measure . 7 . History alcohol substance abuse within 1 year prior screening , deem clinically significant investigator . 8 . Any current malignancy , clinically significant hematological , endocrine , cardiovascular , renal , hepatic , gastrointestinal neurological disease . If condition stable least past year judge investigator interfere patient 's participation study , patient may include . 9 . Clinically significant lab abnormality screen , include Creatinine ≥ 1.7 , B12 laboratory normal reference range TSH site 's laboratory normal reference range . Subjects abnormal B12 TSH level screen may include per investigator 's discretion . 9 . CT MRI evidence follow : hydrocephalus , stroke , spaceoccupying lesion , cerebral infection clinically significant CNS disease FTD . 10.Systolic blood pressure great 180 less 90 mm Hg . Diastolic blood pressure great 105 less 50 mm Hg . 11 . Abnormal ECG screen judge clinically significant investigator . 12 . Use investigational drug participation investigational drug study within 60 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>memantine</keyword>
	<keyword>Namenda</keyword>
	<keyword>Frontotemporal Dementia</keyword>
	<keyword>Semantic Dementia</keyword>
	<keyword>FTD</keyword>
	<keyword>SD</keyword>
	<keyword>dementia</keyword>
	<keyword>behavioral decline</keyword>
	<keyword>cognitive decline</keyword>
</DOC>